Tezepelumab for refractory eosinophilic granulomatosis with polyangiitis-related asthma
Abstract Conventional immunosuppressants are ineffective for the management of EGPA-related asthma. Tezepelumab is a human monoclonal antibody that inhibits thymic stromal lymphopoietin (TLSP) that has proven efficacy in several phase 3 studies for the treatment of asthma. We treated with off-label...
Wedi'i Gadw mewn:
| Prif Awduron: | , , , , , , |
|---|---|
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
BMC
2024-07-01
|
| Cyfres: | Respiratory Research |
| Pynciau: | |
| Mynediad Ar-lein: | https://doi.org/10.1186/s12931-024-02888-x |
| Tagiau: |
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|